$2.52
Today
as of Sep 4, 16:46 ET
Last 30 days
Recent Press Releases & News
ATOS: Multiple Catalysts Converge in 2H26
Atossa Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
Atossa Therapeutics Announces Publication of Novel (Z)-Endoxifen-Related Compounds Demonstrating Potent Anti-Cancer Activity in ER-Positive Breast Cancer
Overview
52-week range
$1.70
$19
5% of range
Avg surprise (last 3)
+3.0%
Avg reaction (last 2)
+2.4%
50% positive
Latest IV / EM
292%
EM ±45.6% · $3 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-0.95 | — | — | — | — | financials |
| Fri May 8, 2026 | Mar/2026 | $-1.11 | $-1.22 | +9.0% | -2,120% | -1.2% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.07 | — | — | — | — | financials |
| Tue Aug 12, 2025 | Jun/2025 | $-0.07 | $-0.06 | -16.7% | — | — | earnings |
| Tue May 13, 2025 | Mar/2025 | $-0.05 | $-0.06 | +16.7% | — | +6.0% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.06 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.05 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.05 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.05 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.08 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.05 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-9M | $-10M | — | $-9M | $-9M | $-7M | — | $-6M |
| Net income | $-8M | $-10M | — | $-9M | $-8M | $-7M | — | $-7M |
| EPS (diluted) | $-0.95 | $-1.11 | — | $-0.07 | $-0.98 | $-0.78 | — | $-0.06 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $26M | $32M | $41M | $52M | $58M | $65M | $71M | $75M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $31M | $37M | $46M | $56M | $63M | $69M | $74M | $77M |
| Total assets | $32M | $38M | $48M | $58M | $65M | $71M | $76M | $79M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $5M | $7M | $8M | $8M | $7M | $5M | $5M | $6M |
| Total equity | $27M | $30M | $39M | $50M | $58M | $65M | $71M | $74M |